NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis → The Next Nvidia? (From InvestorPlace) (Ad) Free TRDA Stock Alerts $13.16 -0.40 (-2.95%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$12.92▼$13.8450-Day Range$11.58▼$14.3552-Week Range$10.62▼$18.44Volume38,162 shsAverage Volume79,645 shsMarket Capitalization$443.23 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Entrada Therapeutics alerts: Email Address Entrada Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside59.6% Upside$21.00 Price TargetShort InterestBearish9.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$119,272 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.54) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector714th out of 904 stocksPharmaceutical Preparations Industry330th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.71% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 23.2, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 1.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 1.1 News and Social Media Coverage Search Interest2 people have searched for TRDA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have bought 695.15% more of their company's stock than they have sold. Specifically, they have bought $119,272.00 in company stock and sold $15,000.00 in company stock.Percentage Held by InsidersOnly 7.58% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.54) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -50.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -50.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About Entrada Therapeutics Stock (NASDAQ:TRDA)Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More TRDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRDA Stock News HeadlinesApril 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,600 SharesApril 14, 2024 | nasdaq.comFriday 4/12 Insider Buying Report: ATOS, TRDAMay 5, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 12, 2024 | insidermonkey.comInsiders are Piling into These 5 Healthcare Stocks in 2024April 11, 2024 | msn.comInsiders Buying America's Car-Mart And 2 Other StocksMarch 27, 2024 | finance.yahoo.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)March 19, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's EstimatesMarch 18, 2024 | markets.businessinsider.comEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical PipelineMay 5, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.March 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)March 13, 2024 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comRecap: Entrada Therapeutics Q4 EarningsMarch 13, 2024 | globenewswire.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Insider TradesJanuary 29, 2024 | finance.yahoo.com‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 StocksJanuary 8, 2024 | finance.yahoo.comAmicus (FOLD) Issues Preliminary Revenue Results for FY23January 6, 2024 | msn.comOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform RecommendationJanuary 3, 2024 | finance.yahoo.comBEAM Stock Rallies More Than 25% in 3 Months: What Next?January 3, 2024 | finance.yahoo.comEntrada Therapeutics Promotes Nathan J. Dowden to PresidentDecember 28, 2023 | finance.yahoo.comEntrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesDecember 20, 2023 | finance.yahoo.comAnavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAADecember 20, 2023 | finance.yahoo.comRoche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagDecember 11, 2023 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comPfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EUNovember 29, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDANovember 29, 2023 | finance.yahoo.comImmunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study DataNovember 27, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To KnowSee More Headlines Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/05/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees159Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$22.00 Low Stock Price Target$20.00 Potential Upside/Downside+59.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,680,000.00 Net Margins-5.18% Pretax Margin9.34% Return on Equity-2.89% Return on Assets-1.39% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual Sales$129.01 million Price / Sales3.44 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book1.81Miscellaneous Outstanding Shares33,680,000Free Float31,125,000Market Cap$443.23 million OptionableNot Optionable Beta-0.38 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Comp: $902.08kMr. Nathan J. Dowden (Age 53)President & COO Comp: $654.6kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Comp: $654.6kMr. Kory James Wentworth CPA (Age 44)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsPepGenNASDAQ:PEPGCorbus PharmaceuticalsNASDAQ:CRBPTheravance BiopharmaNASDAQ:TBPHBiomea FusionNASDAQ:BMEAMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 11,965 shares on 4/30/2024Ownership: 0.044%New York State Teachers Retirement SystemBought 1,915 shares on 4/25/2024Ownership: 0.006%Allspring Global Investments Holdings LLCBought 11,965 shares on 4/18/2024Ownership: 0.044%Peter S KimBought 2,600 shares on 4/8/2024Total: $35,282.00 ($13.57/share)Peter S KimBought 1,512 shares on 3/28/2024Total: $20,790.00 ($13.75/share)View All Insider TransactionsView All Institutional Transactions TRDA Stock Analysis - Frequently Asked Questions Should I buy or sell Entrada Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks. What is Entrada Therapeutics' stock price target for 2024? 2 brokerages have issued 1 year target prices for Entrada Therapeutics' stock. Their TRDA share price targets range from $20.00 to $22.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts. How have TRDA shares performed in 2024? Entrada Therapeutics' stock was trading at $15.09 at the beginning of the year. Since then, TRDA stock has decreased by 12.8% and is now trading at $13.16. View the best growth stocks for 2024 here. When is Entrada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TRDA earnings forecast. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) released its earnings results on Wednesday, March, 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.22. The business had revenue of $41.85 million for the quarter, compared to analysts' expectations of $27.82 million. Entrada Therapeutics had a negative net margin of 5.18% and a negative trailing twelve-month return on equity of 2.89%. What ETF holds Entrada Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,304 shares of TRDA stock, representing 0.45% of its portfolio. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.04%), Allspring Global Investments Holdings LLC (0.04%) and New York State Teachers Retirement System (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher and Peter S Kim. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRDA) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.